Noopept regulatory status
Current status of Noopept in the United States: Unscheduled. In sport: WADA status unclear. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Noopept?
Regulatory: UnscheduledWADA: WADA status unclearVerified: Verified Sep 22, 2026
- FDA and compounding
- Noopept has never been nominated to or reviewed for the FDA 503A or 503B bulks lists and does not appear on the FDA Category 2 page (current as of April 22, 2026). It is not a component of any FDA approved drug. In the United States it is sold as a dietary supplement ingredient, but it is a synthetic drug substance approved in Russia and does not meet the definition of a dietary ingredient, so its sale as a supplement is not an approved use. It is not compoundable under 503A or 503B.
- WADA
- WADA status unclear
- Access path
- Prescription product in Russia and some other former Soviet countries.
- Not an FDA approved drug and not compoundable in the United States.
- Sold online as an unapproved supplement ingredient; identity and purity are not verified.
Full Noopept page: evidence, dosing in the literature, and sources
How has the status of Noopept changed over time?
No dated regulatory event has been recorded for Noopept. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Noopept and the source of each dated event.